Lipofermata, a fatty acid transport protein 2 (FATP2) inhibitor, restrained the activity of PMN-MSDCs and restricted the tumor progression through the STAT5 pathway alone or combined with ICIs [172, 173]. Here, SLC27A2 is linked to neoplasm.